Key result
Baseline ApoC3 and its change with alirocumab did not predict major cardiovascular events, despite alirocumab reducing major cardiovascular events compared to placebo in patients with recent ACS.
Why the study?
Does baseline ApoC3 level or its change with alirocumab predict MACE or death in patients with recent ACS on optimized statin treatment?
RCT (n=11,956)
Does baseline ApoC3 level or its change with alirocumab predict MACE or death in patients with recent ACS on optimized statin treatment?
Answers are grounded in this paper and cite their sources.
In patients with recent ACS on optimized statins, neither baseline ApoC3 nor its change with alirocumab predicted MACE or death after accounting for ApoB.
AIMS: Apolipoprotein (Apo) C3 has been associated with incident coronary heart disease and major adverse cardiovascular events (MACE). Whether ApoC3 levels predict risk in patients with acute coronary syndrome (ACS) on optimized statin treatment is unknown. METHODS: ApoC3 was measured by mass spectrometry at baseline (n=11,956) and after 4 months' treatment (M4; n=11 176) with alirocumab or placebo in the ODYSSEY OUTCOMES trial. Patients with fasting triglycerides >400 mg/dL were excluded. The association of baseline ApoC3 with risk of MACE or death was assessed in post hoc adjusted Cox regression models and spline analyses adjusted for treatment and ApoB. In adjusted models in the alirocumab group we determined association of ApoC3 change from baseline to M4 with subsequent risk of MACE and death. RESULTS: Median (Q1, Q3) baseline ApoC3 concentration was 85 (65, 113) mg/L. With adjustment for ApoB, baseline ApoC3 showed no clinically meaningful relationship to risk of MACE or death in spline analyses and no association with MACE (P=0.89) or death (P=0.70) in Cox regression analyses. Alirocumab reduced ApoC3 modestly by median -10 (-27, -5) mg/L (P<0.0001) and reduced MACE (10.1% vs 12.1%; P=0.0006) and death (3.5% vs 4.2%; P=0.045) versus placebo. However, the change in ApoC3 on alirocumab did not predict subsequent MACE or death. CONCLUSION: In patients with recent ACS on optimized statins without severe hypertriglyceridemia, neither baseline ApoC3 (accounting for ApoB) nor ApoC3 change with alirocumab predicted MACE or death. It is uncertain whether targeted therapies producing larger reductions in ApoC3 from higher baseline levels will affect cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Schwartz et al. (2025) conducted an RCT in Acute coronary syndrome (n=11,956). Alirocumab vs. Placebo was evaluated on MACE (p=0.0006). Baseline ApoC3 and its change with alirocumab did not predict major cardiovascular events, despite alirocumab reducing major cardiovascular events compared to placebo in patients with recent ACS.
Synapse has enriched 10 related papers. Consider them for comparative context: